Trial Profile

A first in human clinical study of UGN-301 as monotherapy and in combination with UGN-201(UGN-302) for treatment of high grade non-muscle invasive bladder cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2022 According to an UroGen Pharma media release, company announced the signing of an up to $100 million term loan financing facility with funds managed by Pharmakon Advisors, L.P, this financing will provide capital to support this trial.
10 Nov 2021 According to an UroGen Pharma media release, the company expect to initiate this study in early 2022.
09 Nov 2020 According to an UroGen Pharma media release, it expects to commence the Phase I program for UGN-302 in the first half of 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com